XOMA Royalty CorpNASDAQ:XOMA
- LAST PRICE33.4000
- TODAY'S CHANGE (%)0.2300 (0.6934%)
- Bid / Lots31.5600/ 1
- Ask / Lots33.9900/ 1
- Open / Previous Close33.4000 / 33.1700
- Day Range
- 52 Week Range
- Volume500
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XOMA |
|---|---|---|
| 09:32 ET | 151 | 33.4 |
Nov 7, 2024
Press Release: XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities, from 7:30AM ET on Thursday Nov 07, 2024 by Dow Jones
7:30AM ET on Thursday Nov 07, 2024 by Dow JonesXOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities, from 7:30AM ET on Thursday Nov 07, 2024 by Dow Jones
7:30AM ET on Thursday Nov 07, 2024 by Dow Jones
Oct 30, 2024
DJ XOMA Royalty Down Nearly 11%, on Pace for Largest Percent Decrease Since January 2023 -- Data Talk, from 11:18AM ET on Wednesday Oct 30, 2024 by Dow Jones
11:18AM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
XOMA Royalty Corp | 390.8M | -10.9x | --- |
Neurogene Inc | 383.3M | -6.0x | --- |
ProQR Therapeutics NV | 388.7M | -12.1x | --- |
Larimar Therapeutics Inc | 423.7M | -5.8x | --- |
Prime Medicine Inc | 432.8M | -1.6x | --- |
Jasper Therapeutics Inc | 348.6M | -5.1x | --- |
Company Information
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, mezagitamab (TAK-079), acimtamig (AFM13), AB054, ficlatuzumab (AV-299), COM902, vosaroxin, aldoxorubicin, INCAGN02385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], CMP-001 (vidutolimod), NTM-1631, NTM-1634, NTM-1633, NTM-1632, NIR178, MK-4830, AFM24, INCAGN01949, AB101, and CFZ533 (iscalimab).
Contact Information
- Headquarters
- 2200 Powell Street, Suite 310EMERYVILLE, CA, United States 94608
- Phone
- 510-204-7239
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Jack Wyszomierski
- Chief Executive Officer, Director
- Owen Hughes
- Chief Financial Officer, Senior Vice President - Finance
- Thomas Burns
- Chief Investment Officer
- Bradley Sitko
- Independent Director
- Heather Franklin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $390.8M |
|---|---|
Revenue (TTM) | $21.6M |
Shares Outstanding | 11.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.88 |
EPS | $-3.06 |
Book Value | $7.72 |
P/E Ratio | -10.9x |
Price/Sales (TTM) | 18.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -154.31% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
